Chikungunya vaccine trial for teens and adults
Part of Infections clinical trials.
This trial tests an experimental chikungunya vaccine (made from a virus-like particle) to see if it prevents the disease. It is for healthy teens and adults who have not had chikungunya before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 12 years old or older
- You are in generally good health (no recent hospital stays or major surgeries)
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use birth control for 8 weeks after the shot
- You have not had a chikungunya vaccine or been diagnosed with chikungunya before
- You do not have a weakened immune system from conditions like HIV, cancer, or long-term steroid use
- You have not had any other vaccines in the last 30 days and won't get any for 3 weeks after the study shot
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This study tests a new vaccine to protect against chikungunya virus, a disease spread by mosquitoes that causes fever and joint pain. The study measures how well your immune system responds to the vaccine and tracks any side effects.
This study tests how well the chikungunya vaccine (IXCHIQ) triggers an immune response in people aged 12 to 59. It is a phase 2 trial to see if the vaccine produces a good antibody response.
This study follows pregnant women who received the VLA1553 vaccine (for chikungunya) to see how it affects them and their babies. It compares them to pregnant women who received a different vaccine approved during pregnancy.
This trial tests whether giving the dengue and chikungunya vaccines together is as safe and effective as giving them separately. If you are a healthy adult, you may be able to help find a more convenient way to protect against these diseases.
This study looks at how well the VLA1553 vaccine prevents chikungunya disease in parts of Brazil where the vaccine is being offered as part of a pilot program. If you live in one of those areas and have had symptoms that might be chikungunya, this study will use your health records and blood tests to check how effective the vaccine is.
Hear when a new Chikungunya Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.